Neuroscientists to Reveal New Insights into Alzheimer's
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
University of California San Francisco
Give to UCSF
Could the Neurons That Make You Scratch Be the Solution for Itch?
Scientists found that the nervous system tamps down allergic response, which could change how asthma, Crohn’s and other inflammatory diseases are treated.
$151M Grant Will Drive New Era in Alzheimer’s Treatments
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
Are New Therapies on the Horizon for Painful Skin Condition?
UCSF's HS PROGRESS study aims to understand and treat Hidradenitis Suppurativa, an often debilitating condition disproportionately affecting women and people of color.
Sandy Feng Elected to the National Academy of Medicine for 2023
UCSF transplant surgeon Sandy Feng, MD, PhD, has been elected to the National Academy of Medicine, one of the most prestigious organizations in health and medicine.
Brief Dialysis May Be Best for Some Kidney Patients
Patients of acute kidney injury might not need as much dialysis as patients with end-stage kidney disease, and might benefit more from weaning off dialysis to avoid risk for heart disease, infection, organ damage and death.
Can a Simple Fentanyl Test Curb San Francisco’s Overdose Crisis?
With fentanyl overdose deaths at an all-time high, a successful UCSF-funded pilot project to distribute fentanyl test strips is being expanded by California Gov. Gavin Newsome as part of his plan to address the crisis.
UCSF Research Vital to First Drug for Deadly Bone Disease
FDA approves palovarotene (Sohonos) for rare FOP, reducing HO by 54%. Significant step in improving lives of affected patients.
Will a Pill Help New Moms Bounce Back from Postpartum Depression?
Zuranolone (Zurzuvae), the first pill for patients suffering from postpartum depression, is expected to be available by the end of 2023. Though it may relieve depressive symptoms, it has some drawbacks such as sedation and dangers in breastfeeding.
